Nymox Announces US NDA for Fexapotide for BPH

7 years ago

by David Miller

962 Views

Written by David Miller

HASBROUCK HEIGHTS, N.J., Feb. 05, 2018 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US. The…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!